Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Mutations in the tumor suppressor p53 (p53) are prevalent in approximately 50% of human cancers.
• These mutations lead to loss of tumor suppressive functions, dominant-negative effects, and oncogenic gain-of-function activities.
• p53 mutations are cancer-specific, making them attractive therapeutic targets.

Purpose of the Study:

• To review clinically available FDA-approved drugs and drugs in clinical trials that target p53 mutations.
• To summarize the mechanisms of action for these drugs.
• To evaluate their efficacy in suppressing cancer progression.

Main Methods:

• Literature review of FDA-approved drugs and clinical trial candidates targeting p53 mutations.
• Analysis of drug mechanisms, including restoration of wild-type p53, rescue of nonsense mutations, degradation of mutant p53, and synthetic lethality induction.
• Summary of drug activities against cancer progression.

Main Results:

• Several therapeutic strategies are being investigated to target p53 mutations.
• These strategies include restoring wild-type p53 conformation, rescuing nonsense mutations, degrading mutant p53, and exploiting synthetic lethality.
• Drugs targeting p53 mutations show promise in suppressing cancer progression.

Conclusions:

• Targeting p53 mutations represents a promising strategy in cancer therapy.
• A range of therapeutic approaches are under investigation, with several drugs in clinical trials.
• Further research and clinical development are crucial to fully realize the therapeutic potential of targeting p53 mutations.